Literature DB >> 15212725

Mitral Valve Repair in the Treatment of Heart Failure.

Michael M. Madani1.   

Abstract

Heart failure continues to be one of the leading causes of hospitalizations and mortality in the United States. Mitral valve regurgitation in patients with heart failure is most often a functional abnormality and as such represents a different disease entity from other more common causes of regurgitation. In general, in patients with heart failure the mitral valve structure is normal; however, regurgitation is secondary to changes in left ventricular (LV) structure and function, including mitral annular dilatation and changes in LV geometry. Mitral regurgitation affects almost all patients with heart failure as a preterminal or terminal event, and carries a high morbidity and mortality. Medical management is limited to treatment with diuretics and afterload reduction. Unfortunately, once significant amounts of mitral regurgitation are manifest, medical treatment alone is generally associated with poor long-term survival and outcome. Surgical treatment by means of undersized annuloplasty type repairs has shown great promise, for preventing worsening heart failure and improving overall LV function.

Entities:  

Year:  2004        PMID: 15212725     DOI: 10.1007/s11936-004-0032-5

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  9 in total

Review 1.  Robotic mitral valve surgery.

Authors:  Alan P Kypson; L Wiley Nifong; W Randolph Chitwood
Journal:  Semin Thorac Cardiovasc Surg       Date:  2003-04

Review 2.  Surgical alternatives for heart failure.

Authors:  S F Bolling; I A Smolens; F D Pagani
Journal:  J Heart Lung Transplant       Date:  2001-07       Impact factor: 10.247

3.  How leaky is that mitral valve? Simplified Doppler methods to measure regurgitant orifice area.

Authors:  J D Thomas
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

Review 4.  Mitral valve reconstruction in the patient with heart failure.

Authors:  S F Bolling
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

5.  Intermediate-term outcome of mitral reconstruction in cardiomyopathy.

Authors:  S F Bolling; F D Pagani; G M Deeb; D S Bach
Journal:  J Thorac Cardiovasc Surg       Date:  1998-02       Impact factor: 5.209

Review 6.  ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease).

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

7.  Restricted coronary flow reserve in patients with mitral regurgitation improves after mitral reconstructive surgery.

Authors:  T Akasaka; K Yoshida; T Hozumi; T Takagi; S Kaji; T Kawamoto; Y Ueda; Y Okada; S Morioka; J Yoshikawa
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

8.  Mitral valve repair in patients with end stage cardiomyopathy: who benefits?

Authors:  Jan F Gummert; Axel Rahmel; Jan Bucerius; Jörg Onnasch; Nicolas Doll; Thomas Walther; Volkmar Falk; Friedrich W Mohr
Journal:  Eur J Cardiothorac Surg       Date:  2003-06       Impact factor: 4.191

9.  Utility of transesophageal echocardiography during port-access minimally invasive cardiac surgery.

Authors:  R M Applebaum; W M Cutler; N Bhardwaj; S B Colvin; A C Galloway; G H Ribakove; E A Grossi; D S Schwartz; R V Anderson; P A Tunick; I Kronzon
Journal:  Am J Cardiol       Date:  1998-07-15       Impact factor: 2.778

  9 in total
  2 in total

1.  Inferolateral left ventricular aneurysm preventing mitral regurgitation.

Authors:  Sakir Arslan; H Yekta Gurlertop; M Kemal Erol; Fuat Gundogdu; Huseyin Senocak
Journal:  Tex Heart Inst J       Date:  2007

2.  Biventricular pacing: impact on exercise-induced increases in mitral insufficiency in patients with chronic heart failure.

Authors:  Klaus K Witte; Zion Sasson; Joan A Persaud; Robynn Jolliffe; Robert W Wald; John D Parker
Journal:  Can J Cardiol       Date:  2008-05       Impact factor: 5.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.